TechCrunch(@TechCrunch):Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally

TechCrunch

@TechCrunch

Technology news and analysis with a focus on founders and startup teams. Got a tip?

Joined March 2007

460 Following 11M Followers

TechCrunch@TechCrunch

2026.08.29 17:39

Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally